Biodexa Pharmaceuticals Plc (BDRX) stock forecast & analysis
0.7300
NasdaqCM · USD
Down: -0.0699, -8.7%
0.7100Down: -0.0200, -2.7%
1 analysis
- Open
- 0.7795
- Previous close
- 0.7999
- Day range
- 0.7100 – 0.8325
- 52-week range
- 0.6100 – 59.40
- Volume (shares)
- 553.44K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 1.03M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 1.19
- Market cap
- 751.22K
Market Scanner’s AI analysis of Biodexa Pharmaceuticals Plc (BDRX), updated September 2026: Biodexa Pharmaceuticals Plc (BDRX) recent analyses covered a strong 7-day price surge against a backdrop of negative profitability and longer-term downtrends.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Biodexa Pharmaceuticals Plc (BDRX) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Biodexa Pharmaceuticals Plc (BDRX) recent analyses covered a strong 7-day price surge against a backdrop of negative profitability and longer-term downtrends.
Recent analyses for Biodexa Pharmaceuticals Plc (BDRX) examined its financial performance, noting negative profitability with a negative EPS and ROE, and a negative gross profit for the trailing twelve months. The company's interim results for the six months ended June 30, 2026, were released, with no other significant news. Market analysis highlighted a strong 7-day price increase, but indicated bearish medium and long-term trends based on moving averages and longer-term price changes.
BDRX news & sentiment
News reports indicated mixed sentiment for European equities, with no specific news items for BDRX in the past week.
BDRX technical picture
The stock showed a strong 7-day upward price movement, contrasting with significant longer-term downtrends. Price action was below both the 50-day and 200-day Simple Moving Averages, indicating bearish medium and long-term trends. Momentum readings were neutral, while the Money Flow Index suggested significant buying pressure.
Fundamentals
The company Biodexa Pharmaceuticals Plc (BDRX) reported negative profitability with a negative EPS and ROE, and a negative gross profit for the trailing twelve months. Revenue figures were not provided for the periods analyzed.
Factors discussed — upside
- Strong 7-day price change of +53.3%
- Money Flow Index (MFI) at 99.05 suggesting significant buying pressure
Factors discussed — risks
- Negative profitability with negative EPS and ROE
- Negative gross profit for the trailing twelve months
- Significant downtrend over the 30-day and 91-day periods
- Stock price below both 50-day and 200-day Simple Moving Averages
- Financial Performance
- Stock Price Trends
- Technical Indicators
- Company News
Summary updated .
BDRX technical indicators
Common technical indicators for BDRX, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.39 | Price below |
| 10-day exponential moving average | 0.93 | Price below |
| Relative strength index (14-day) | 38.97 | Neutral |
| MACD line (12/26/9) | -0.1459 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.54 – 1.35 | Price inside the bands |
Analyses
Recent BDRX.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Biodexa Pharmaceuticals Plc?
- Recent analyses highlighted a strong 7-day price increase for Biodexa Pharmaceuticals Plc (BDRX), accompanied by a Money Flow Index (MFI) of 99.05, suggesting significant buying pressure.
- What are the risks for Biodexa Pharmaceuticals Plc?
- The analyses noted Biodexa Pharmaceuticals Plc's (BDRX) negative profitability, including a negative EPS and ROE, along with a negative gross profit. Furthermore, the stock price is below its 50-day and 200-day moving averages, and longer-term trends over 30 and 91 days have been downwards.
- Is Biodexa Pharmaceuticals Plc bullish or bearish?
- Recent AI analyses of Biodexa Pharmaceuticals Plc examined factors on both sides. Discussed upside: Recent analyses highlighted a strong 7-day price increase for Biodexa Pharmaceuticals Plc (BDRX), accompanied by a Money Flow Index (MFI) of 99.05, suggesting significant buying pressure. Discussed risks: The analyses noted Biodexa Pharmaceuticals Plc's (BDRX) negative profitability, including a negative EPS and ROE, along with a negative gross profit. Furthermore, the stock price is below its 50-day and 200-day moving averages, and longer-term trends over 30 and 91 days have been downwards. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Biodexa Pharmaceuticals Plc?
- News reports indicated mixed sentiment for European equities, with no specific news items for BDRX in the past week.
- How does Market Scanner analyse Biodexa Pharmaceuticals Plc?
- Every analysis of Biodexa Pharmaceuticals Plc runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh BDRX.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every BDRX.US report already in the library